CVTrader is a self-taught investor who started trading in early 2000 at the height of the tech bubble. Having learned many lessons in the subsequent downward ride, he adopted a value-oriented, comparative analysis-guided investing strategy. With a Ph.D. in biological science and working experience in the biotech/pharmaceutical industry, he pays special attention to small- and mid-cap biopharmaceutical companies with innovative products and solid balance sheets. At the same time, he does recognize that equity trading is not an exact science, and that market can be irrational at times, so he also employs other techniques mainly leveraged ETFs to capitalize on short-term market swings.
Douglas Krohn is a physician in private practice who provides biotechnology analysis. Dr. Krohn employs an evidence-based, peer-reviewed approach to his evaluation of pipeline biotechnology products. He is a graduate of the Albert Einstein College of Medicine, completed his pediatric residency at Montefiore Medical Center in the Bronx, and is a former columnist for The Cornell Daily Sun.
Our Man in NYC is a Brit, and as such you can expect proper spelling (the benefits of a classical education), who has worked in the investment industry since college graduation (bar a brief period to acquire 3 additional letters, and enjoy the Manhattan that passed him by while working). While by day he's forced to scavenge among the trees in equity-world, by night he roams above the forest and lets his random macro, thematic and inquisitive side wander...
CVTrader is a self-taught investor who started trading in early 2000 at the height of the tech bubble. Having learned many lessons in the subsequent downward ride, he adopted a value-oriented, comparative analysis-guided investing strategy. With a Ph.D. in biological science and working experience in the biotech/pharmaceutical industry, he pays special attention to small- and mid-cap biopharmaceutical companies with innovative products and solid balance sheets.
At the same time, he does recognize that equity trading is not an exact science, and that market can be irrational at times, so he also employs other techniques mainly leveraged ETFs to capitalize on short-term market swings.
China has become the #2 pharmaceutical market years ahead of projections and continues to be the fastest growing market in the world. China is $50 billion dollars a year into life science and healthcare development through over 160 government funding programs. VC investment, M&A transactions and cross-border partnering deals in China were all up significantly in 2012.
ChinaBio® Today focuses exclusively on the rapidly evolving life science industry in China, including biotech, pharma, medical device, diagnostics, services and tools. From our offices in Shanghai and San Diego, our industry analysts provide daily news, commentary and analysis on public and private China life science companies, as well as events and global issues affecting the China market.
Visit: ChinaBio Today (http://www.chinabiotoday.com)
ChinaBio LLC (http://www.chinabiollc.com)
China OTC Player/Rising China Stocks, a blog run by China OTC Player and Platinum Tiger, focuses on uncovering the hidden potential in emerging Chinese stocks. They are MBAs (Stanford and Wharton) based in Los Angeles who have lived and worked in Singapore, China, Hong Kong, and other parts of the world, sometimes as investment professionals and sometimes in other fields. Their mission is to enlighten, enthuse and entertain as they pursue profits via investment in China's new growth companies.
Visit their blog: China OTC Player/Rising China Stocks (http://chinaotcplayer.blogspot.com/)
I write about dividend growth stocks on my website www.dividendgrowthinvestor.com.
I am mostly a buyer of high quality dividend stocks, with solid competitive advantages. My holding period is forever, as long as the dividend is at least maintained. I tend to concentrate my efforts on stocks which grow earnings and dividends, which provides outstanding total returns over time. I only focus my attention to stocks with sustainable dividend payments. I am also a firm believer in diversification accross sectors and geographic locations.
I have been focusing my attention particularly to companies that regularly increase dividends to their shareholders on my website. On my blog I share my thoughts on investing in dividend paying stocks that have consistently increased their payments over time and tips on growing my dividend income. I hope that my blog will serve as an inspiration for my readers and that it would change their financial lives for the better.
Visit my website, Dividend Growth Investor (http://www.dividendgrowthinvestor.com/)
Justin M. Hall is an extremely accomplished independent financial analyst with more than a decade of experience in the financial markets. He consistently provides expertise to a variety of financial clients and is known for his successful market predictions. Between 2010 and 2014 Justin made 239 specific market recommendations via his online subscription service with an 80% accuracy rate. He has produced enduring results for a variety of clients including those who trade stocks, invest their own money, desire personal wealth management, and institutional investors. But more than an analyst, Justin is a person who influences and persuades, whose judgement is well respected and highly trusted, and whose opinion is sought by those searching for financial and investment advice.
Justin received his undergraduate degree from Indiana State University and attended law school at Indiana University. His desire to serve the financial and investment needs of individual clients led him to start Rx Investors.com, an online subscription service that connected individual investors with his expert analysis. Subscribers from all over the world utilized Justin’s advice to generate market income and grow their individual portfolios. Many of these subscribers and clients continued to seek Justin’s analysis and advice for many years, appreciating his unique perspective on the financial industry.
A variety of financial outlets have recognized Justin’s expertise and highlighted his work including the Orange County Business Journal, Seeking Alpha, and Zack’s Investment Research. These industry connections have allowed Justin to lend his expert advice to others and expand his influence.
Mike Havrilla is a former pharmacist (retail and home infusion settings), biotech stock trader, and writer with experience that includes full-time online trading since 2009, working as a full-time pharmacist from 2004-2009, and writing for investors since 2007. Mike holds Doctor of Pharmacy (PharmD) and Bachelor of Science (Biology) degrees from the University of Pittsburgh and worked in the pharmaceutical industry for Wyeth prior to pharmacy school. He is also an avid runner and has completed over 20 marathons with a personal best time under three hours for the 26.2 mile race and under 80 minutes for the half marathon. Mike merged his former publishing business with BioRunUp.com / Mark Messier in October 2010, creating a new online biotech stock research and trading subscription service.
Founder of Old School Value (www.oldschoolvalue.com).
Fundamental Stock Analyzer & Valuation Tool for Value Investors to Save Time & Make Money
- Are you spending a lot of time manually gathering and inputting data into spreadsheets?
- Are you finding it difficult to keep up to date with fundamental company valuations?
- Do you need a way to quickly check whether a company is worth investigating?
- Do you want to know what a company is worth quickly?
The Old School Value Stock Analysis Software is a fundamental analysis and valuation tool that works for you.
Save hours each day by automatically retrieving and crunching the financials for thousands of companies.
Keep up to date easily and find more opportunities by analyzing companies faster and use the 5 valuation models to cross check whether the stock price is an attractive entry price or time to get out.
Learn more at http://try.oldschoolvalue.com/stock-analyzer/